Brian Peter Zambrowicz
Directeur/Membre du Conseil chez Texas A&M Institute for Genomic Medicine
Postes actifs de Brian Peter Zambrowicz
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Texas A&M Institute for Genomic Medicine
 Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Brian Peter Zambrowicz
Anciens postes connus de Brian Peter Zambrowicz
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/09/1995 | 24/02/2015 |
| Fondateur | 07/07/1995 | 24/02/2015 | |
| NUEVOLUTION AB (PUBL) | Directeur/Membre du Conseil | - | - |
| Corporate Officer/Principal | - | - |
Formation de Brian Peter Zambrowicz
| University of Wisconsin | Undergraduate Degree |
| University of Washington | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Danemark | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Texas A&M Institute for Genomic Medicine
Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Commercial Services |
Nuevolution AB
 Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Bourse
- Insiders
- Brian Peter Zambrowicz
- Expérience
